Claims

1. A composition comprising one or more unit doses of a PCSK9-binding fusion protein having the amino acid sequence of SEQ ID NO:3, the unit dose containing from 250 mg to 350 mg of the PCSK9-binding fusion protein formulated at a concentration of at least 200 mg/mL; and a pharmaceutically-acceptable carrier.

2. The composition of claim 1, wherein the unit dose has a concentration of at least 250 mg/mL of the PCSK9-binding fusion protein.

3. The composition of claim 1, wherein the unit dose has a concentration of at least 300 mg/mL of the PCSK9-binding fusion protein.

4. The composition of claim 1, wherein the pharmaceutically-acceptable carrier comprises a buffering agent, an isotonicity agent, a solvent, and optionally a surfactant.

5. The composition of claim 4, wherein the buffering agent comprises one or more of an amino acid buffer, citrate buffer, a phosphate buffer, an acetate buffer, succinate buffer, and a bicarbonate buffer.

6. The composition of claim 5, wherein the buffering agent comprises L-Histidine/L-Histidine monohydrochloride.

7. The composition of claim 5, wherein the isotonicity agent comprises one or more of sodium chloride, dextrose, sucrose, glycerin, mannitol, sorbitol, arginine, and potassium chloride.

8. The composition of claim 7, wherein the isotonicity agent comprises sodium chloride.

9. The composition of claim 4, wherein the pharmaceutically-acceptable carrier comprises polysorbate-80.

10. The composition of claim 4, wherein the composition does not comprise a surfactant.

11. The composition of claim 4, wherein the solvent is water.

12. An injection pen comprising the composition of claim 1.

13. The injection pen of claim 12, wherein the injection pen contains from 1 to 10 unit doses.

14. The injection pen of claim 13, wherein the unit doses are no more than 1.5 mL in volume.

15. The injection pen of claim 14, wherein the unit doses are no more than 1 mL in volume.